Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - HC Wainwright increased their Q2 2025 earnings estimates for shares of Sage Therapeutics in a research report issued on Wednesday, April 30th. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will earn ($0.94) per share for the quarter, up from their prior forecast of ($1.05). HC Wainwright has a "Neutral" rating and a $12.00 price target on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. HC Wainwright also issued estimates for Sage Therapeutics' Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.86) EPS, FY2025 earnings at ($3.70) EPS, FY2026 earnings at ($3.03) EPS, FY2027 earnings at ($2.51) EPS, FY2028 earnings at ($2.14) EPS and FY2029 earnings at ($1.42) EPS.
A number of other equities research analysts have also commented on SAGE. Bank of America assumed coverage on Sage Therapeutics in a research report on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 price target on the stock. Wedbush reissued a "neutral" rating and set a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Canaccord Genuity Group lowered their price target on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a report on Wednesday, February 12th. StockNews.com raised shares of Sage Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, Scotiabank lowered their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating for the company in a research note on Wednesday, February 12th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and two have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $8.81.
Get Our Latest Stock Analysis on SAGE
Sage Therapeutics Price Performance
Shares of Sage Therapeutics stock traded up $0.03 during trading on Friday, hitting $6.89. The company's stock had a trading volume of 197,602 shares, compared to its average volume of 1,219,270. The stock has a market cap of $431.15 million, a price-to-earnings ratio of -1.05 and a beta of 0.20. Sage Therapeutics has a 52 week low of $4.62 and a 52 week high of $13.47. The stock has a 50-day moving average price of $7.54 and a two-hundred day moving average price of $6.77.
Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The business had revenue of $14.06 million for the quarter, compared to analyst estimates of $14.12 million. During the same quarter in the prior year, the business earned ($1.80) earnings per share. The firm's quarterly revenue was up 78.0% on a year-over-year basis.
Institutional Investors Weigh In On Sage Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Thrivent Financial for Lutherans increased its holdings in Sage Therapeutics by 108.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 38,876 shares in the last quarter. Amundi bought a new stake in Sage Therapeutics during the fourth quarter worth $166,000. Geode Capital Management LLC raised its position in Sage Therapeutics by 0.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company's stock valued at $8,975,000 after buying an additional 3,757 shares during the last quarter. SG Americas Securities LLC lifted its stake in Sage Therapeutics by 57.7% during the 4th quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock valued at $122,000 after acquiring an additional 8,228 shares in the last quarter. Finally, Empowered Funds LLC purchased a new position in Sage Therapeutics during the 4th quarter worth $91,000. Institutional investors and hedge funds own 99.22% of the company's stock.
Sage Therapeutics Company Profile
(
Get Free Report)
Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.
See Also
Before you consider Sage Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sage Therapeutics wasn't on the list.
While Sage Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
